$1.65 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Oncorus

Oncorus, Inc. is a clinical stage biopharmaceutical company focused on developing viral immunotherapies for cancer patients. The Company is leveraging its platforms to develop a pipeline of intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. The Company is developing a differentiated portfolio of locally and systemically administered oncolytic virus therapies across its oncolytic Herpes Simplex Virus (oHSV) and Synthetic Virus Platform. Its lead product candidates are ONCR-177, ONCR-GBM, Synthetic Coxsackievirus (CV)A21 and Synthetic Seneca Valley Virus (SVV).

Stock Analysis

last close $1.51
1-mo return 17.1%
3-mo return 24.8%
avg daily vol. 62.12T
52-week high 11.81
52-week low 0.98
market cap. $39M
forward pe -
annual div. -
roe -56.4%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 70.9%

Subscribe now for daily local and international financial news